Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.42 |
| ▸ | HTR2C | P28335 | 4/20 | 0.42 |
| ▸ | HTR2B | P41595 | 3/20 | 0.42 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | KMO | O15229 | 5/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.35 |
| ▸ | HTR1A | P08908 | 2/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | HTR1D | P28221 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4539850 | 0.81 | HTR2A (0.40) | HTR2AHTR2CHTR2BKMOCYP1A2 | |
| SCHEMBL6741175 | 0.78 | HTR2A (0.46) | HTR2AHTR2CHTR2BBRD4KMO | |
| Ammonia Solution, Strong SCHEMBL8009916 | 0.77 | HTR2A (0.45) | HTR2AHTR2CHTR2BKMOHTR1A | |
| SCHEMBL4539220 | 0.77 | MCHR1 (0.47) | HTR2AHTR2CHTR2B | |
| SCHEMBL8007547 | 0.76 | HTR2A (0.55) | HTR2AHTR2CHTR2BKMOHTR1A | |
| SCHEMBL30860226 | 0.74 | HTR2A (0.41) | HTR2AHTR2CHTR2BBRD4KMO | |
| SCHEMBL3784975 | 0.73 | CHRM2 (0.41) | HTR2AHTR2CHTR2BBRD4KMO | |
| SCHEMBL21057855 | 0.73 | HDAC1 (0.48) | HTR2AHTR2CBRD4KMOCHRM2 | |
| SCHEMBL3779615 | 0.72 | KMO (0.42) | HTR2AHTR2CHTR2BKMOCHRM2 | |
| SCHEMBL2144057 | 0.72 | NOTUM (0.44) | HTR2AHTR2CHTR2BKMOCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084485-B2 | 6-(aminoalkyl)indazoles | VITAE PHARMACEUTICALS, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20100331287-A1 | 6-(Aminoalkyl)Indazoles | VITAE PHARMACEUTICALS, INC. | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331287-A1 | 6-(Aminoalkyl)Indazoles | REN, AGTR1, AGTR2 | HTR2A 1966/4885HTR2C 1984/4885HTR2B 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.